Please assess the completion status of the following clinical trial:

Trial Title: Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have a diagnosis of clinically definite MS with a relapsing disease course as determined by the Poser criteria~2. Patients must be on high dose interferon therapy (Betaseron® 250 µg or Rebif® 44 µg) for at least 1 year prior to study entry~3. Patients must have experienced at least one documented relapse during the past year prior to screening. Pseudo-relapses must be ruled out. A gadolinium enhancing lesion is not required.~4. Patients must be ambulatory, with a Kurtzke EDSS score between 0-5 inclusive~5. Patients must be between the ages of 18 and 50 years inclusive~6. Women of childbearing potential must practice an acceptable method of birth control. Acceptable methods include oral contraceptive, contraceptive patch, long-acting injectable contraceptive, double-barrier method (condom or IUD with spermicide), or partner's vasectomy~7. Patients must be relapse-free and off corticosteroids (IV or oral) for at least 30 days prior to the screening visit~8. Patients must be relapse-free and off corticosteroids between the screening and baseline visits~9. Patients must be willing and able to give written informed consent~Exclusion Criteria:~1. Use of experimental or investigational drugs, and/or participation in an investigational drug study within 6 months prior to study entry~2. Previous treatment with glatiramer acetate (injectable)~3. Previous treatment with immunomodulators (except IFNβ), immunosuppressive agents, IVIG, or plasma exchange in the 6 months prior to screening; previous treatment with cladribine in the past 2 years~4. Previous total body irradiation or total lymphoid irradiation~5. Chronic corticosteroid (IV, IM, and/or PO) treatment (more than 30 consecutive days) in the 6 months prior to study entry~6. Pregnancy or breastfeeding~7. Life-threatening or other clinically significant disease~8. Any condition which the investigator feels may interfere with participation in the study, including alcohol and/or drug abuse~9. A known sensitivity to gadolinium (gadolinium acid)~10. A known history of sensitivity to mannitol~11. Inability to successfully undergo MRI scanning

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Glatiramer Acetate 20 mg s.c. daily
- 2 (Type: ACTIVE_COMPARATOR): Betaseron 250 ug every other day or Rebif 44 ug 3 times a week

Based on this trial design, predict the completion outcome and termination type (if applicable).